Cargando…

Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1

BACKGROUND: IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, affecting close to a million people. Circulating galactose-deficient IgA (gd-IgA), present in patients with IgAN, form immune complex deposits in the glomerular mesangium causing local proliferation and matrix exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebefors, Kerstin, Liu, Peidi, Lassén, Emelie, Elvin, Johannes, Candemark, Emma, Levan, Kristina, Haraldsson, Börje, Nyström, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820936/
https://www.ncbi.nlm.nih.gov/pubmed/27044423
http://dx.doi.org/10.1186/s12882-016-0251-5
_version_ 1782425499727822848
author Ebefors, Kerstin
Liu, Peidi
Lassén, Emelie
Elvin, Johannes
Candemark, Emma
Levan, Kristina
Haraldsson, Börje
Nyström, Jenny
author_facet Ebefors, Kerstin
Liu, Peidi
Lassén, Emelie
Elvin, Johannes
Candemark, Emma
Levan, Kristina
Haraldsson, Börje
Nyström, Jenny
author_sort Ebefors, Kerstin
collection PubMed
description BACKGROUND: IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, affecting close to a million people. Circulating galactose-deficient IgA (gd-IgA), present in patients with IgAN, form immune complex deposits in the glomerular mesangium causing local proliferation and matrix expansion. Intriguing though, individuals having gd-IgA deposits in the kidneys do not necessarily have signs of glomerular disease. Recurrence of IgAN only occurs in less than half of transplanted patients with IgAN, indicating that gd-IgA is not the only factor driving the disease. We hypothesize that, in addition to IgA complexes, patients with IgAN possess a subtype of mesangial cells highly susceptible to gd-IgA induced cell proliferation. METHODS: To test the hypothesis, we designed a technique to culture primary mesangial cells from renal biopsies obtained from IgAN patients and controls. The cell response to gd-IgA treatment was then measured both on gene and protein level and the proliferation rate of the cells in response to PDGF was investigated. RESULTS: When treated with gd-IgA, mesangial cells from patients with IgAN express and release more PDGF compared to controls. In addition, the mesangial cells from patients with IgAN were more responsive to treatment with PDGF resulting in an increased proliferation rate of the cells compared to control. Mesangial cells cultured from patients with IgAN expressed and released more IL-6 than controls and had a higher expression of matrix genes. Both mesangial cells derived from patients with IgAN and controls increased their expressed TGFβ1 and CCL5 when treated with gd-IgA. CONCLUSION: We conclude that mesangial cells derived from IgAN patients have a mesangioproliferative phenotype with increased reactivity to IgA and that these cellular intrinsic properties may be important for the development of IgA nephropathy.
format Online
Article
Text
id pubmed-4820936
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48209362016-04-06 Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1 Ebefors, Kerstin Liu, Peidi Lassén, Emelie Elvin, Johannes Candemark, Emma Levan, Kristina Haraldsson, Börje Nyström, Jenny BMC Nephrol Research Article BACKGROUND: IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, affecting close to a million people. Circulating galactose-deficient IgA (gd-IgA), present in patients with IgAN, form immune complex deposits in the glomerular mesangium causing local proliferation and matrix expansion. Intriguing though, individuals having gd-IgA deposits in the kidneys do not necessarily have signs of glomerular disease. Recurrence of IgAN only occurs in less than half of transplanted patients with IgAN, indicating that gd-IgA is not the only factor driving the disease. We hypothesize that, in addition to IgA complexes, patients with IgAN possess a subtype of mesangial cells highly susceptible to gd-IgA induced cell proliferation. METHODS: To test the hypothesis, we designed a technique to culture primary mesangial cells from renal biopsies obtained from IgAN patients and controls. The cell response to gd-IgA treatment was then measured both on gene and protein level and the proliferation rate of the cells in response to PDGF was investigated. RESULTS: When treated with gd-IgA, mesangial cells from patients with IgAN express and release more PDGF compared to controls. In addition, the mesangial cells from patients with IgAN were more responsive to treatment with PDGF resulting in an increased proliferation rate of the cells compared to control. Mesangial cells cultured from patients with IgAN expressed and released more IL-6 than controls and had a higher expression of matrix genes. Both mesangial cells derived from patients with IgAN and controls increased their expressed TGFβ1 and CCL5 when treated with gd-IgA. CONCLUSION: We conclude that mesangial cells derived from IgAN patients have a mesangioproliferative phenotype with increased reactivity to IgA and that these cellular intrinsic properties may be important for the development of IgA nephropathy. BioMed Central 2016-04-05 /pmc/articles/PMC4820936/ /pubmed/27044423 http://dx.doi.org/10.1186/s12882-016-0251-5 Text en © Ebefors et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ebefors, Kerstin
Liu, Peidi
Lassén, Emelie
Elvin, Johannes
Candemark, Emma
Levan, Kristina
Haraldsson, Börje
Nyström, Jenny
Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title_full Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title_fullStr Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title_full_unstemmed Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title_short Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1
title_sort mesangial cells from patients with iga nephropathy have increased susceptibility to galactose-deficient iga1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820936/
https://www.ncbi.nlm.nih.gov/pubmed/27044423
http://dx.doi.org/10.1186/s12882-016-0251-5
work_keys_str_mv AT ebeforskerstin mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT liupeidi mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT lassenemelie mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT elvinjohannes mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT candemarkemma mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT levankristina mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT haraldssonborje mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1
AT nystromjenny mesangialcellsfrompatientswithiganephropathyhaveincreasedsusceptibilitytogalactosedeficientiga1